Literature DB >> 21253308

Liver cirrhosis induced by porphyria cutanea tarda: a case report and review.

Kwang Gyun Lee1, Jong Jin Hyun, Yeon Seok Seo, Bora Keum, Hyung Joon Yim, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim, Ho Sang Ryu, Soon Ho Um.   

Abstract

Porphyria cutanea tarda (PCT) is a metabolic disorder that results in a decrease in uroporphyrinogen decarboxylase activity. It is characterized by photosensitivity, bullae formation, and skin pigmentation. There are four types of PCT: acquired, familial, toxic, and hepatoerythropoietic. Uroporphyrin levels are elevated in the urine of PCT patients. PCT can be differentiated from other porphyrias by its clinical characteristics and the porphyrin levels in the serum, erythrocytes, urine, and feces. This metabolic disorder can lead to liver dysfunction as well as histological changes such as fatty infiltration or hepatic fibrosis. PCT rarely manifests as liver cirrhosis. We report herein a case of PCT-induced liver cirrhosis that progressed to hepatic failure.

Entities:  

Keywords:  Liver cirrhosis; Metabolic disorder; Porphyria cutanea tarda; Uroporphyrin

Year:  2010        PMID: 21253308      PMCID: PMC3021615          DOI: 10.5009/gnl.2010.4.4.551

Source DB:  PubMed          Journal:  Gut Liver        ISSN: 1976-2283            Impact factor:   4.519


  31 in total

Review 1.  Alcohol intake and porphyria cutanea tarda.

Authors:  G H Elder
Journal:  Clin Dermatol       Date:  1999 Jul-Aug       Impact factor: 3.541

Review 2.  Porphyria cutanea tarda.

Authors:  N R Bleasel; G A Varigos
Journal:  Australas J Dermatol       Date:  2000-11       Impact factor: 2.875

3.  [Biological diagnosis of porphyria cutanea tarda].

Authors:  Y Nordmann
Journal:  Ann Dermatol Venereol       Date:  2000-10       Impact factor: 0.777

4.  [Pathology of the skin appendages in porphyria cutanea tarda].

Authors:  D Pizzino; M De Padova; M Labanca; C Varotti
Journal:  G Ital Dermatol Venereol       Date:  1988-11       Impact factor: 2.011

Review 5.  Porphyria cutanea tarda.

Authors:  C Fritsch; K Lang; S von Schmiedeberg; K Bolsen; H Merk; P Lehmann; T Ruzicka
Journal:  Skin Pharmacol Appl Skin Physiol       Date:  1998 Nov-Dec

Review 6.  The management of porphyria cutanea tarda.

Authors:  R P Sarkany
Journal:  Clin Exp Dermatol       Date:  2001-05       Impact factor: 3.470

7.  Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT).

Authors:  Jérĵme Lamoril; Christophe Andant; Laurent Gouya; Eva Malonova; Bernard Grandchamp; Pavel Martásek; Jean-Charles Deybac; Hervé Puy
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2002-02       Impact factor: 1.770

8.  The significance of histologic analysis of skin lesions in porphyria cutanea tarda. Light microscopy, electron microscopy, immunohistochemical and immunofluorescence analysis.

Authors:  I Krajnc; A Vizjak; A Hvala; V Jurcić; B Rozman
Journal:  Wien Klin Wochenschr       Date:  1998-10-02       Impact factor: 1.704

Review 9.  Iron overload in porphyria cutanea tarda.

Authors:  M Sampietro; G Fiorelli; S Fargion
Journal:  Haematologica       Date:  1999-03       Impact factor: 9.941

10.  Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease.

Authors:  A L Fracanzani; E Taioli; M Sampietro; E Fatta; C Bertelli; G Fiorelli; S Fargion
Journal:  J Hepatol       Date:  2001-10       Impact factor: 25.083

View more
  1 in total

1.  Chimeric Mouse With Humanized Liver Is an Appropriate Animal Model to Investigate Mode of Action for Porphyria-Mediated Hepatocytotoxicity.

Authors:  Ayumi Eguchi; Satoki Fukunaga; Keiko Ogata; Masahiko Kushida; Hiroyuki Asano; Samuel M Cohen; Tokuo Sukata
Journal:  Toxicol Pathol       Date:  2021-07-09       Impact factor: 1.902

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.